All News

Article

ACR 2020 Your Way - Get Your Topic Emails

Jack Cush, MD

ACR is but a few days away; the question is: how will you tackle this virtual meeting? RheumNow has created several options for learning the way you want to. First is to feed your need. Are you a lupologist? A gout maven? A Spondylitis sleuth? A drug safety wannabe?

Article

Abatacept in Early Systemic Sclerosis (ASSET study)

Jack Cush, MD

An open-label extension of the ASSET trial (abatacept in diffuse cutaneous systemic sclerosis) showed continued safety with significant improvements in the modified Rodnan Skin Score (mRSS) at 12 months, suggesting abatacept (ABA) may benefit early systemic sclerosis (SSc).

Article

FDA Invites Patient Input on Systemic Sclerosis Drug Development

Jack Cush, MD

While there have been several promising new agents for systemic sclerosis, many have failed - with all noting the difficulties in appropriate outcomes and endpoints for clinical trials. With this in mind, the FDA was interested in hearing patients’ perspectives on systemic sclerosis and new drug development, and held a virtual meeting on 10/13/20.

Article

Slow Lung Decline Typical in Systemic Sclerosis

RheumNow

The interstitial lung disease that develops in a subset of patients with systemic sclerosis tends to be heterogeneous, with the majority of patients experiencing a slow pattern of decline in lung function, analysis of outcomes in the European Scleroderma Trials and Research (EUSTAR) database foun

Dr. John Cush Tweet
RheumNow
Review of 127 pts w/ diagnostic criteria for palindromic rheumatism - Most affected JTS were wrist, knee, MCP; 34% later developed CTD (28% RA, 2% lupus 3% other CTD). Progression predicted by +RF (HR 2.9), PIP (HR 2.4), Wrist (HR 2.5) & female (HR 2.2)
Dr. John Cush Tweet
RheumNow
259 SLE patients followed an 80% were in lupus low disease activity state (LLDAS); 82% in remission; 19% w/ active dz. 56 pst in subjective Low activity (SLQ<6) compared to SLAQ>6, latter had more arthritis, fibromyalgia and took steroids https://t.co/IdeSNlaEOG
Dr. John Cush Tweet
RheumNow
Observational study of 123 Spanish rheumatic dz pts w/ COVID-19, finds 54 hospitalized. Admitted pts were 69.7 yrs, and 22% died. Admission was assoc w/ older age, autoimmune dz (vs inflammatory arthritis; OR: 3.55), but not DMARD Rx. https://t.co/UWNyhOKbvF
Dr. John Cush Tweet
RheumNow
Lockdown worsening; UK survey 678 patients musculoskeletal diseases pts in late April 2020 shows 53% worsening of Sx; 1/3 had clinic/hosp access probs problems & most (88%) had no probs w/ getting meds; but 44% needed others to help them get meds. https://t.co/3efmTdHhQx
Dr. John Cush Tweet
RheumNow
Among 4766 mental health pts admited for Psychosis; 19% ANA tested and only 135 had a positive ANA >=1:160. (15% of those tested). Only 4 met 2019 ACR/EULAR criteria for SLE, and 2/4 met criteria for NPSLE. NPSLE prevalence was 1.5% in ANA+ psychosis Pts. https://t.co/c5C1VQaQAI
k dao Tweet
KDAO2011
"Prednisone >30 mg/day for > 4 weeks, patients should be on PJP prophylaxis." Image shows when to start/stop PJP prophylaxis Dr. Kevin Winthrop on Risks/Prevention of OI @UTSWRheum Grand Rounds @rheumnow https://t.co/nXuWYRxbgy
Dr. John Cush Tweet
RheumNow
Predictors of Remission in SLE? metanalysis of 17270 SLE pts; 42-88% achieved remission x 1 yr, & 21-70% for 5 yrs. Remission assoc w/ older age , lower Dz activity & No major organ involvement; positive serologies negatively associated w/ remission https://t.co/2aoGgnY6kw
Dr. John Cush Tweet
RheumNow
Complement assoc. studied by Petri & Durcan in 2399 SLE pts. 55% had low C3 (pesistently low 4%); 47% low C4 (3% persistently low). Low C4 is weak marker clinical & serological Dz. Low C3 linked w/ renal & serological Dz, Low C3/C4 linked to ACL, CVA, DVT https://t.co/KgF7HNEYu8
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×